Clinical trials: Anticoagulation
Venous Thromboembolism
Safety and Efficacy of Therapeutic Anticoagulation With Tinzaparin During Pregnancy Via Weight-based Dosing
The purpose of this study is to evaluate the safety and efficacy of therapeutic anticoagulation with tinzaparin during pregnancy via weight-based dosing.
- Trial name
- NCT00851864
- Testing
- Tinzaparin
- Where
- Canada
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Primary PCI - STEMI
STEMI Treated With Primary Angioplasty and Intravenous Lovenox or Unfractionated Heparin (UFH)
Randomized evaluation of enoxaparin (0.5mg/kg IV) versus UFH (50-70IU/kg with GPIIb/IIIa inhibitors; 70-100IU without GPIIb/IIIa inhibitors).
- Trial name
- ATOLL (NCT00718471)
- Testing
- Enoxaparin, UFH (unfractionated heparin)
- Where
- France
- Volunteers
- 910 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Sinus Thrombosis, Intracranial
Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis
Background: Endovascular thrombolysis, with or without mechanical clot removal (ET), may be beneficial for a subgroup of patients with cerebral venous sinus thrombosis (CVT), who have a poor prognosis despite treatment with…
- Trial name
- TOACT (NCT01204333)
- Testing
- Endovascular thrombolysis, Heparin
- Where
- 15 sites in Canada, China and 4 more
- Volunteers
- 67 people
- Sponsor
- Jan Stam, MD, PhD
Coronary Artery Disease, Atrial Fibrillation
Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation
The investigators hypothesize that reducing the duration of clopidogrel therapy from 6 months to 6 weeks after DES implantation is associated with improved clinical outcomes in patients on ASA and an oral anticoagulant.
- Trial name
- ISAR-TRIPLE (NCT00776633)
- Testing
- aspirin, clopidogrel, oral anticoagulation
- Where
- 3 sites in Denmark, Germany
- Volunteers
- 614 people
- Sponsor
- Deutsches Herzzentrum Muenchen
PE - Pulmonary Embolism, PE - Pulmonary Thromboembolism
FlowTriever All-Comer Registry for Patient Safety and Hemodynamics
To evaluate the safety and effectiveness of the FlowTriever System for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism (PE).
- Trial name
- FLASH (NCT03761173)
- Testing
- FlowTriever System, Anticoagulation Agents
- Where
- 81 sites in United States, Austria and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Inari Medical
Atrial Fibrillation
Anticoagulation After RFCA
The anticoagulation therapy is needed when rhythm control strategy is applied in atrial fibrillation patients but adverse events such as major bleeding exist.
- Trial name
- Reducible (NCT03573037)
- Testing
- Oral anticoagulant
- Where
- South Korea
- Volunteers
- 246 people
- Sponsor
- Yong Seog Oh
ECMO
PACE: Prostacyclin AntiCoagulation in ECMO
Extracorporeal membrane oxygenation (ECMO) is a machine that temporarily supports the heart and/or lungs and is a critical rescue therapy for refractory cardiac and respiratory failure in pediatric populations.
- Trial name
- PACE (NCT07837869)
- Testing
- Dose-escalation study of epoprostenol as adjunct anticoagulation in ECMO
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Garrett Keim
Acute Kidney Injury
Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?
Anticoagulation-Related Nephropathy (ARN) is a side effect of treatment with blood thinners which leads to kidney dysfunction. A recent review suggests that kidney function should be assessed (by measuring serum creatinine)…
- Trial name
- NCT02900170
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Albert Einstein Healthcare Network
ATRIAL FIBRILLATION
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF
This is a prospective, multicenter, randomized, double-blinded clinical trial exploring the efficacy and safety of rivaroxaban as compared to standard of care in reducing stroke, transient ischemic attack (TIA) and neurocognitive…
- Trial name
- BRAIN-AF (NCT02387229)
- Testing
- Rivaroxaban, standard of care
- Where
- 41 sites in Canada
- Volunteers
- 1,238 people
- Sponsor
- Montreal Heart Institute
Atrial Fibrillation (AF)
Research on Post-Stroke Anticoagulation Strategies for Atrial Fibrillation Based on Left Atrial Appendage Flow Velocity Measured by Intracardiac Echocardiography (ICE)
1. Study Purpose The primary aim of this research was to systematically describe and characterize a novel, thrombus-mimicking artifact observed during Intracardiac Echocardiography (ICE), termed the "Floating Lotus" sign.
- Trial name
- NCT07439731
- Testing
- Intracardiac Echocardiography (ICE) for Differential Diagnosis
- Where
- 2 sites in China
- Volunteers
- 172 people
- Sponsor
- Changhai Hospital
Lymphoma, Acute Lymphoblastic Leukemia
A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase
The purpose of this study is to compare the effect of a blood thinning drug called Apixaban versus no administration of a blood thinning drug, in preventing blood clots in children with leukemia or lymphoma.
- Trial name
- NCT02369653
- Testing
- Apixaban, No systemic anticoagulant prophylaxis
- Where
- 96 sites in United States, Australia and 10 more
- Volunteers
- 512 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation, Atrial Flutter
Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
The purpose of this research study is to test an experimental drug ATI-5923 vs Coumadin. The study is intended to demonstrate ATI-5923 is superior to Coumadin for keeping INR values in the desired therapeutic range.
- Conditions
- Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction
- Trial name
- EmbraceAC (NCT00691470)
- Testing
- ATI-5923, Coumadin (warfarin)
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- ARYx Therapeutics
Atrial Fibrillation, Coronary Artery Disease
Comparison Between Direct Oral Anticoagulation (DOAC) Interruption and DOAC Continuation in Patients Undergoing Elective Invasive Coronary Angiography or Percutaneous Coronary Intervention
A prospective, multicenter, 1:1 randomized, investigator initiated study. Goal of this study is to examine the safety of uninterrupted periprocedural DOAC use.
- Conditions
- Atrial Fibrillation, Coronary Artery Disease, Anticoagulants
- Trial name
- SLIM-2 (NCT04977076)
- Testing
- Uninterrupted DOAC use, Interrupted DOAC use
- Where
- Netherlands
- Volunteers
- 1,270 people
- Sponsor
- Zuyderland Medisch Centrum
Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication
Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMO
The SURVIVE trial aims to test whether using an anti-thrombotic regimen involving cangrelor can reduce bleeding risk while maintaining effective antithrombotic effects in patients on VA-ECMO due to cardiogenic shock (CS)/ cardiac…
- Conditions
- Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication, Platelet Dysfunction
- Trial name
- SURVIVE (NCT06792643)
- Testing
- Cangrelor
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Pediatric HD
EXCOR® Pediatric VAD Anticoagulation IDE
The Berlin Heart EXCOR ventricular assist device received approval from the FDA as a bridge to transplantation for children in 2011.
- Trial name
- NCT03702192
- Testing
- novel anticoagulation protocol used in conjunction with the Berlin Heart EXCOR
- Sponsor
- David N. Rosenthal
Acute Respiratory Failure, SARS CoV 2 Infection
Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients
Coronavirus Disease (COVID-19) is characterized by a hypercoagulable state, sometimes difficult to be managed with heparin. Bivalirudin, a member of the direct thrombin inhibitor drug class, offers potential advantages compared…
- Conditions
- Acute Respiratory Failure, SARS CoV 2 Infection, Anticoagulants
- Trial name
- NCT05334654
- Testing
- Enoxaparin Sodium, Bivalirudin
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University Magna Graecia
Extracorporeal Clotting During Hemodialysis
Effect of Nephral 400 ST Dialysis Membrane on Coagulation in Hemodialysis
The purpose of this study is to investigate whether the dialysis filter AN69ST (Nephral 400 ST Dialysis Membrane) induces less clotting during hemodialysis than a conventional polysulphone filter.
- Trial name
- NCT00594607
- Testing
- AN69ST dialysis membrane, Fx8 (Fresenius)
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- Ullevaal University Hospital
Atrial Fibrillation, End Stage Renal Disease
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
This is a prospective, randomized, open-label, blinded end-point evaluation trial. The patient population consists of patients on hemodialysis who have atrial fibrillation (AF) and end-stage renal disease (ESRD) .
- Trial name
- RENAL-AF (NCT02942407)
- Testing
- apixaban, warfarin
- Where
- 58 sites in United States
- Volunteers
- 154 people
- Sponsor
- Christopher Granger, MD
Kidney Replacement Disorder
Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy
Actual clinical practice predominantly makes use of heparin (systemically) or citrate regionally as anticoagulation in the extracorporeal circulation for renal replacement therapy.
- Trial name
- NCT01276392
- Where
- Germany
- Sponsor
- Klinik für Anästhesiologie
Venous Thromboembolism
Remote Home Prothrombin Time (PT)/International Normalized Ratio (INR) Monitoring and Patient Management System
Long-term anticoagulation is indicated in patients for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or mechanical cardiac valve replacement, prevention or treatment…
- Trial name
- vMetrics-AMS (NCT00978445)
- Testing
- vMetrics protocol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- ZIN Technologies, Inc.